Blockade of RAGE in Zucker obese rats with experimental periodontitis

被引:15
作者
Grauballe, M. B. [1 ]
Ostergaard, J. A. [2 ,3 ,4 ]
Schou, S. [5 ]
Flyvbjerg, A. [2 ,3 ]
Holmstrup, P. [1 ,6 ]
机构
[1] Aarhus Univ, Sect Periodontol, Dept Odontol, Fac Hlth, Vennelyst Blvd 9, DK-8000 Aarhus C, Denmark
[2] Aarhus Univ, Med Res Labs, Dept Clin Med, Fac Hlth, Aarhus, Denmark
[3] Aarhus Univ Hosp, Dept Endocrinol & Internal Med, Aarhus, Denmark
[4] Univ Copenhagen, Danish Diabet Acad, Copenhagen, Denmark
[5] Univ Copenhagen, Sect Oral & Maxillofacial Surg, Copenhagen, Denmark
[6] Univ Copenhagen, Sect Periodontol Microbiol & Community Dent, Dept Odontol, Fac Hlth & Med Sci, Copenhagen, Denmark
基金
英国医学研究理事会;
关键词
animal models; obese diabetic Zucker rats; periodontitis; receptor of advanced glycation end-products; type; 2; diabetes; GLYCATION END-PRODUCTS; TUMOR-NECROSIS-FACTOR; FACTOR-KAPPA-B; INSULIN-RESISTANCE; DIABETES-MELLITUS; BONE LOSS; FACTOR-ALPHA; TNF-ALPHA; RECEPTOR; DISEASE;
D O I
10.1111/jre.12373
中图分类号
R78 [口腔科学];
学科分类号
1003 ;
摘要
Background and ObjectivePeriodontitis and type 2 diabetes mellitus (T2D) are two interrelated chronic diseases. Periodontitis is more prevalent in patients with T2D than in healthy subjects, and studies indicate that periodontitis impacts the metabolic control of patients with T2D. Hyperglycemia in T2D leads to the formation of advanced glycation end-products (AGEs). Binding of AGEs to the receptor of AGE (RAGE) elicits an increased inflammatory response that may be a key modulator linking the two diseases. The present study aimed to elucidate the effect of blocking the RAGE on the interrelationship between periodontitis and T2D in a rat model of both diseases. Material and methodsZucker obese rats (HsdHlr:ZUCKER-Lepr(fa/fa)) and their lean littermates were divided into five treatment groups, with and without periodontitis. Monoclonal anti-RAGE IgG(3) were injected into the rats three times a week. The diabetic state was evaluated by oral glucose tolerance tests (OGTTs), the homeostasis model assessment (HOMA), concentration of free fatty acids and repeated measurements of blood glucose. Markers of systemic inflammation, including interleukin (IL)-1, IL-6 and tumor necrosis factor , were evaluated in plasma. Kidney complications were evaluated by quantitative real-time PCR, the creatinine clearance rate, the albumin excretion rate and kidney hypertrophy. Periodontitis was evaluated by morphometric registration of alveolar bone loss and radiographic recording of bone support. ResultsThe diabetic state was improved by antibody treatment for 4 wk, resulting in a lower area under the glucose concentration curve during OGTTs, lower insulin levels and a lower HOMA. Furthermore, the antibody treatment resulted in milder kidney complications, as evaluated by measuring the albumin excretion rate and the kidney weight. There was no impact of periodontal inflammation on the level of complications. Periodontal bone support was influenced by diabetes, but the altered diabetic status as a result of treatment with anti-RAGE Ig had no effect on periodontitis. ConclusionIn this study, treatment with anti-RAGE IgG(3) resulted in improved glucose tolerance and attenuated renal complications. However, no effect was observed on the diabetes-associated periodontitis in Zucker obese rats. Furthermore, periodontitis had no effect on diabetic markers or renal complications. Therefore, activation of RAGE is important in the development of T2D.
引用
收藏
页码:97 / 106
页数:10
相关论文
共 42 条
  • [1] The relationship between receptor for advanced glycation end products expression and the severity of periodontal disease in the gingiva of diabetic and non diabetic periodontitis patients
    Abbass, Marwa Magdy
    Korany, Nahed Sedky
    Salama, Ahmed Helmy
    Dmytryk, John J.
    Safiejko-Mroczka, Barbara
    [J]. ARCHIVES OF ORAL BIOLOGY, 2012, 57 (10) : 1342 - 1354
  • [2] Melatonin ameliorates low-grade inflammation and oxidative stress in young Zucker diabetic fatty rats
    Agil, Ahmad
    Reiter, Russel J.
    Jimenez-Aranda, Aroa
    Iban-Arias, Ruth
    Navarro-Alarcon, Miguel
    Antonio Marchal, Juan
    Adem, Abdu
    Fernandez-Vazquez, Gumersindo
    [J]. JOURNAL OF PINEAL RESEARCH, 2013, 54 (04) : 381 - 388
  • [3] Periodontitis deteriorates metabolic control in type 2 diabetic Goto-Kakizaki rats
    Andersen, Carla C. Pontes
    Buschard, Karsten
    Flyvbjerg, Allan
    Stoltze, Kaj
    Holmstrup, Palle
    [J]. JOURNAL OF PERIODONTOLOGY, 2006, 77 (03) : 350 - 356
  • [4] Diabetes-associated sustained activation of the transcription factor nuclear factor-κB
    Bierhaus, A
    Schiekofer, S
    Schwaninger, M
    Andrassy, M
    Humpert, PM
    Chen, J
    Hong, M
    Luther, T
    Henle, T
    Klöting, I
    Morcos, M
    Hofmann, M
    Tritschler, H
    Weigle, B
    Kasper, M
    Smith, M
    Perry, G
    Schmidt, AM
    Stern, DM
    Häring, HU
    Schleicher, E
    Nawroth, PP
    [J]. DIABETES, 2001, 50 (12) : 2792 - 2808
  • [5] The influence of diet consistence, drinking water and bedding on periodontal disease in Sprague-Dawley rats
    Björnsson, MJ
    Velschow, S
    Stoltze, K
    Havemose-Poulsen, A
    Schou, S
    Holmstrup, P
    [J]. JOURNAL OF PERIODONTAL RESEARCH, 2003, 38 (06) : 543 - 550
  • [6] The role of TNF-α in insulin resistance
    Borst, SE
    [J]. ENDOCRINE, 2004, 23 (2-3) : 177 - 182
  • [7] Long-term AICAR administration reduces metabolic disturbances and lowers blood pressure in rats displaying features of the insulin resistance syndrome
    Buhl, ES
    Jessen, N
    Pold, R
    Ledet, T
    Flyvbjerg, A
    Pedersen, SB
    Pedersen, O
    Schmitz, O
    Lund, S
    [J]. DIABETES, 2002, 51 (07) : 2199 - 2206
  • [8] Glycated matrix up-regulates inflammatory signaling similarly to Porphyromonas gingivalis lipopolysaccharide
    Chang, P-C.
    Chien, L-Y.
    Chong, L. Y.
    Kuo, Y-P.
    Hsiao, J-K.
    [J]. JOURNAL OF PERIODONTAL RESEARCH, 2013, 48 (02) : 184 - 193
  • [9] Receptor for advanced glycation end products in bacterial infection: is there a role for immune modulation of receptor for advanced glycation end products in the treatment of sepsis?
    Christaki, Eirini
    Lazaridis, Nikolaos
    Opal, Steven M.
    [J]. CURRENT OPINION IN INFECTIOUS DISEASES, 2012, 25 (03) : 304 - 311
  • [10] De Vriese AS, 2003, J AM SOC NEPHROL, V14, P2109, DOI 10.1681/ASN.V1482109